Albert David Limited Reports Q2 FY26 Results: Revenue Declines, Net Loss Narrows

Albert David Limited , a pharmaceutical manufacturing company, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company reported a decline in revenue but managed to narrow its losses compared to the previous quarter.

Financial Highlights

Particulars (Rs. in Lakhs)	Q2 FY26	Q1 FY26	H1 FY26
Revenue from Operations	5,857.00	7,056.64	13,779.18
Net Loss	540.04	779.76	526.71

Revenue and Profitability

Albert David Limited's revenue from operations for Q2 FY26 stood at Rs. 5,857.00 lakhs, marking a decrease from Rs. 7,056.64 lakhs in the previous quarter. Despite the revenue decline, the company managed to reduce its net loss to Rs. 540.04 lakhs in Q2 FY26, compared to a loss of Rs. 779.76 lakhs in Q1 FY26.

For the half-year period ended September 30, 2025, the company reported a total revenue from operations of Rs. 13,779.18 lakhs, with a cumulative net loss of Rs. 526.71 lakhs.

Dividend Announcement

During the quarter, Albert David Limited paid a dividend of Rs. 5.00 per equity share, resulting in a total outflow of Rs. 285.36 lakhs. This dividend payout demonstrates the company's commitment to returning value to its shareholders despite challenging market conditions.

Operational Overview

Albert David Limited operates in the pharmaceutical manufacturing sector, with a single reportable segment as per Ind AS-108 "Operating Segments". The company's financial results were reviewed by the Audit Committee and approved by the Board of Directors.

Balance Sheet and Cash Flow

As of September 30, 2025, Albert David Limited reported total assets of Rs. 53,294.06 lakhs, compared to Rs. 51,141.56 lakhs as of March 31, 2025. The company's total equity stood at Rs. 39,389.66 lakhs, showing a slight increase from Rs. 39,248.34 lakhs at the end of the previous fiscal year.

The cash flow statement reveals that the company faced challenges in its operating activities, with a net cash outflow of Rs. 2,084.59 lakhs for the half-year ended September 30, 2025. However, the company saw positive cash flow from financing activities, primarily due to proceeds from current borrowings.

Management Commentary

Y. M. Kunte, Managing Director & CEO of Albert David Limited, signed off on the financial results. While specific management comments were not provided in the available data, the company's efforts to reduce losses in a challenging quarter are evident from the financial figures.

Auditor's Review

The statutory auditors have conducted a limited review of the financial results for the quarter and half-year ended September 30, 2025, as required under SEBI regulations. They have issued an unmodified review report, indicating that the financial statements are free from material misstatements.

Investors and stakeholders should note that these are unaudited results and may be subject to changes upon final audit. The pharmaceutical sector continues to face various challenges, and Albert David Limited's performance reflects the ongoing market dynamics in this industry.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.96%	-2.43%	-12.01%	-3.35%	-43.82%	+71.69%

Albert David , a prominent pharmaceutical company, has successfully appointed Dr. Rajiv Anant Desai as an Independent Director following overwhelming shareholder approval through a postal ballot. The special resolution for Dr. Desai's appointment received near-unanimous support, with 99.99% of votes cast in favor.

Appointment Details

Dr. Rajiv Anant Desai will serve as an Independent Director for a five-year term, commencing from August 2, 2025, to August 1, 2030. The appointment was approved through a postal ballot process, which included electronic voting (e-voting) to ensure wide participation and adherence to corporate governance norms.

Voting Process and Participation

The e-voting process for the postal ballot ran from August 18 to September 16, 2025. Out of the total 15,227 shareholders on record, 135 participated in the voting process. The breakdown of voting results is as follows:

Category	Votes in Favor	Votes Against	% in Favor
Promoter & Promoter Group	3,551,958	0	100.00%
Public - Institutional	118,491	0	100.00%
Public - Non-Institutional	9,759	471	95.40%
Total	3,680,208	471	99.99%

The special resolution was passed with an overwhelming majority, demonstrating strong shareholder confidence in Dr. Desai's appointment.

Dr. Rajiv Anant Desai's Profile

Dr. Desai brings a wealth of experience and expertise to Albert David. His qualifications include:

M.Sc. in Chemistry from Mumbai University
Ph.D. in Pharmaceutical Chemistry from ICT Mumbai Institute of Chemical Technology
MBA from NMIMS, Mumbai

With over 38 years of experience in the pharmaceutical industry, both in India and Switzerland, Dr. Desai has an impressive track record. He previously served as Executive Vice President, Global Corporate Quality at Lupin Limited until June 2022. Currently, he works as a Senior Technical Advisor with the Indian Pharmaceutical Alliance.

Company's Statement

Lalit Lohia, Company Secretary & Compliance Officer of Albert David, confirmed the appointment in a statement to the stock exchanges. The company emphasized that Dr. Desai is not related to any Director or Key Managerial Personnel of Albert David and is not debarred from holding the office of Director by any regulatory authority.

The appointment of Dr. Rajiv Anant Desai as an Independent Director is expected to bring valuable insights and expertise to Albert David's board, potentially contributing to the company's growth and governance in the coming years.